Specimen Transport
Articles & Testing Guides
Education
Outreach Resource Center
- Support Services
- Operations
- Sales and Marketing
- Billing and Finance
- Regulatory
- Examples
- More Resources
- Contact Outreach Team
| Web: | MayoMedicalLaboratories.com |
|---|---|
| Email: | mml@mayo.edu |
| Telephone: | 800.533.1710 |
| International: | 507.266.5700 |
| Values are valid only on day of printing. | |
Diagnosis of C3 deficiency
Investigation of a patient with undetectable total complement
(CH[50]) level
Complement proteins are components of the innate immune
system. There are 3 pathways to complement activation: 1) the
classic pathway, 2) the alternative (or properdin) pathway, and 3)
the lectin activation (mannan-binding protein [MBP]) pathway. The
classic pathway of the complement system is composed of a series
of proteins that are activated in response to the presence of immune
complexes. The activation process results in the generation of
peptides that are chemotactic for neutrophils and that bind to immune
complexes and complement receptors. The end result of the
complement activation cascade is the formation of the lytic
membrane attack complex (MAC).
The absence of early components (C1-C4) of the complement
cascade results in the inability of immune complexes to activate
the cascade. Patients with deficiencies of the early complement
proteins are unable to clear immune complexes or to generate
lytic activity. These patients have increased susceptibility to
infections with encapsulated microorganisms. They may also have
symptoms that suggest autoimmune disease and complement
deficiency may be an etiologic factor in the development of
autoimmune disease.
C3 is at the entry point for all 3 activation pathways to activate the
MAC. C3 deficiency may result in pneumococcal and neisserial
infections as well as autoimmune diseases such as glomerulonephritis.
Complement levels can be detected by antigen assays that
quantitate the amount of the protein (#8174 "Complement C3,
Serum"). For most of the complement proteins, a small number of
cases have been described in which the protein is present but is
non functional. These rare cases require a functional assay to
detect the deficiency.
21-50 unit/mL
Low levels of complement may be due to inherited deficiencies,
acquired deficiencies, or due to complement consumption (e.g.,
as a consequence of infectious or autoimmune processes).
Absent C3 levels in the presence of other normal complement
values are consistent with a C3 deficiency.
The total complement assay (#8167 "Complement, Total, Serum")
should be used as a screen for suspected complement deficiencies
before ordering individual complement component assays. A
deficiency of an individual component of the complement cascade
will result in an undetectable total complement level.
Absent (or low) C3 functional levels in the presence of normal C3
antigen levels should be replicated with a new serum specimen
to confirm that C3 inactivation did not occur during shipping.
1. Davis ML, Austin C, Messmer BL, et al: IFCC-standardization
pediatric reference intervals for 10 serum proteins using the
Beckman Array 360 system. Clin Biochem 1996;29(5):489-492
2. Gaither TA, Frank MM: Complement. In Clinical Diagnosis and
Management by Laboratory Methods. 17th edition. Edited by
JB Henry. Philadelphia, WB Saunders Company, 1984, pp 879-892
3. O'Neil KM: Complement deficiency. Clin Rev Allergy Immunol
2000;19:83-108
4. Frank MM: Complement deficiencies. Pediatr Clin North Am
2000;47(6):1339-1354